Drugs / DA-3002
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02770157 | Feb 2016 → Aug 2019 | fetal growth restriction | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01813630 | Feb 2013 → May 2018 | Turner syndrome | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01786902 | Feb 2012 → Apr 2014 | isolated short stature | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DA-3002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02770157 ↗ |
| Known as | Growtropin-II | “the efficacy and safety of a new recombinant human GH, Growtropin®-II (DA-3002, Dong-A ST Co., Ltd) versus a comparator (Genotropin®, Pfizer Inc.)” PMID 34893062 ↗ Dec 2021 |
| Modality | Protein / enzyme biologic | “Recombinant Human Growth Hormone” NCT01786902 ↗ |
| Route | Subcutaneous | “given by subcutaneous injections” NCT01786902 ↗ |